Pomalidomide and lenalidomide induce p21WAF-1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanism

Cancer Research

Volumn 69, Issue 18, 2009, Pages 7347-7356

  Escoubet Lozach, Laure ^a   Lin, I Lin ^a   Jensen Pergakes, Kristen ^a   Brady, Helen A ^a   Gandhi, Anita K ^a   Schafer, Peter H ^a   Muller, George W ^a   Worland, Peter J ^a   Chan, Kyle W H ^a   Verhelle, Dominique ^a  

^a CELGENE CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1; EARLY GROWTH RESPONSE FACTOR 1; EARLY GROWTH RESPONSE FACTOR 2; HISTONE DEACETYLASE; HISTONE H3; LENALIDOMIDE; LYSINE SPECIFIC DEMETHYLASE 1; POMALIDOMIDE; PROTEIN P53; RNA POLYMERASE II; TRANSCRIPTION FACTOR SP1; TRANSCRIPTION FACTOR SP3; UNCLASSIFIED DRUG;

ACETYLATION; ARTICLE; CANCER MODEL; CHROMATIN STRUCTURE; CONTROLLED STUDY; DNA METHYLATION; DRUG MECHANISM; EPIGENETICS; GC RICH SEQUENCE; HUMAN; HUMAN CELL; LYMPHOMA; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; RNA INTERFERENCE; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION; UPREGULATION;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CHROMATIN; CYCLIN-DEPENDENT KINASE INHIBITOR P21; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONES; HUMANS; LYMPHOMA; MULTIPLE MYELOMA; OXIDOREDUCTASES, N-DEMETHYLATING; THALIDOMIDE; TRANSCRIPTION FACTORS;

EID: 70349739288     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-4898     Document Type: Article

References (49)

1. Hideshima T, Chauhan D, Shima Y, et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 2000;96:2943-2950 (Pubitemid 30815199)
2. Bartlett JB, Dredge K, Dalgleish AG. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer 2004;4:314-322 (Pubitemid 38525287)
3. Corral LG, Haslett PA, Muller GW, et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-α. J Immunol 1999;163:380-386
4. Davies FE, Raje N, Hideshima T, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001;98:210-216
5. Dredge K, Marriott JB, Macdonald CD, et al. Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects. Br J Cancer 2002;87:1166-1172 (Pubitemid 35418112)
6. Gandhi AK, Kang J, Naziruddin S, Parton A, Schafer PH, Stirling DI. Lenalidomide inhibits proliferation of Namalwa CSN.70 cells and interferes with Gab1 phosphorylation and adaptor protein complex assembly. Leuk Res 2006;30:849-858 (Pubitemid 43816707)
7. List AF. Lenalidomide - the phoenix rises. N Engl J Med 2007;357:2183-2186
8. Weber DM, Chen C, Niesvizky R, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007;357:2133-2142 (Pubitemid 350146108)
9. List A, Kurtin S, Roe DJ, et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 2005;352:549-557
10. + cells. J Clin Invest 2008;118:248-258
11. + progenitor cells. Cancer Res 2007;67:746-755
12. el-Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993;75:817-825
13. 1 arrest and apoptosis. Cancer Res 1994;54:1169-1174
14. Gartel AL, Tyner AL. Transcriptional regulation of the p21((WAF1/CIP1)) gene. Exp Cell Res 1999;246:280-289
15. Choi BH, Kim CG, Bae YS, Lim Y, Lee YH, Shin SY. p21 Waf1/Cip1 expression by curcumin in U-87MG human glioma cells: role of early growth response-1 expression. Cancer Res 2008;68:1369-1377 (Pubitemid 351346844)
16. Chen B, He L, Savell VH, Jenkins JJ, Parham DM. Inhibition of the interferon-γ/signal transducers and activators of transcription (STAT) pathway by hypermethylation at a STAT-binding site in the p21WAF1 promoter region. Cancer Res 2000;60:3290-3298 (Pubitemid 30407929)
17. Roman-Gomez J, Castillejo JA, Jimenez A, et al. 5′ CpG island hypermethylation is associated with transcriptional silencing of the p21(CIP1/WAF1/SDI1) gene and confers poor prognosis in acute lymphoblastic leukemia. Blood 2002;99:2291-2296
18. Sterner DE, Berger SL. Acetylation of histones and transcription-related factors. Microbiol Mol Biol Rev 2000;64:435-459
19. Nian H, Delage B, Pinto JT, Dashwood RH. Allyl mercaptan, a garlic-derived organosulfur compound, inhibits histone deacetylase and enhances Sp3 binding on the P21WAF1 promoter. Carcinogenesis 2008;29:1816-1824
20. Wang LG, Liu XM, Fang Y, et al. De-repression of the p21 promoter in prostate cancer cells by an isothiocyanate via inhibition of HDACs and c-Myc. Int J Oncol 2008;33:375-380
21. Duan Z, Zarebski A, Montoya-Durango D, Grimes HL, Horwitz M. Gfi1 coordinates epigenetic repression of p21Cip/WAF1 by recruitment of histone lysine methyltransferase G9a and histone deacetylase 1. Mol Cell Biol 2005;25:10338-10351 (Pubitemid 41681959)
22. Shi Y, Lan F, Matson C, et al. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell 2004;119:941-953 (Pubitemid 40037608)
23. Metzger E, Wissmann M, Yin N, et al. LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription. Nature 2005;437:436-439 (Pubitemid 41613508)
24. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005;102:15545-15550 (Pubitemid 41528093)
25. Xie X, Lu J, Kulbokas EJ, et al. Systematic discovery of regulatory motifs in human promoters and 3′ UTRs by comparison of several mammals. Nature 2005;434:338-345
26. Labhart P, Karmakar S, Salicru EM, et al. Identification of target genes in breast cancer cells directly regulated by the SRC-3/AIB1 coactivator. Proc Natl Acad Sci U S A 2005;102:1339-1344 (Pubitemid 40214365)
27. Sawka-Verhelle D, Escoubet-Lozach L, Fong AL, et al. PE-1/METS, an antiproliferative Ets repressor factor, is induced by CREB-1/CREM-1 during macrophage differentiation. J Biol Chem 2004;279:17772-17784 (Pubitemid 38560544)
28. Metivier R, Penot G, Hubner MR, et al. Estrogen receptor-α directs ordered, cyclical, and combinatorial recruitment of cofactors on a natural target promoter. Cell 2003;115:751-763 (Pubitemid 38030303)
29. Squazzo SL, O'Geen H, Komashko VM, et al. Suz12 binds to silenced regions of the genome in a cell-type-specific manner. Genome Res 2006;16:890-900. (Pubitemid 43992913)
30. Wenz HM, Ramachandra S, O'Connell CD, Atha DH. Identification of known p53 point mutations by capillary electrophoresis using unique mobility profiles in a blinded study. Mutat Res 1998;382:121-132 (Pubitemid 28341973)
31. Lombo F, Menendez N, Salas JA, Mendez C. The aureolic acid family of antitumor compounds: structure, mode of action, biosynthesis, and novel derivatives. Appl Microbiol Biotechnol 2006;73:1-14. (Pubitemid 44627719)
32. Kurdistani SK, Tavazoie S, Grunstein M. Mapping global histone acetylation patterns to gene expression. Cell 2004;117:721-733 (Pubitemid 38748889)
33. Hollstein M, Rice K, Greenblatt MS, et al. Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res 1994;22:3551-3555 (Pubitemid 24299821)
34. Weller M. Predicting response to cancer chemotherapy: the role of p53. Cell Tissue Res 1998;292:435-445 (Pubitemid 28282455)
35. El-Deiry WS. Insights into cancer therapeutic design based on p53 and TRAIL receptor signaling. Cell Death Differ 2001;8:1066-1075
36. O'Connor PM, Jackman J, Jondle D, Bhatia K, Magrath I, Kohn KW. Role of the p53 tumor suppressor gene in cell cycle arrest and radiosensitivity of Burkitt's lymphoma cell lines. Cancer Res 1993;53:4776-4780 (Pubitemid 23326165)
37. Albertini V, Jain A, Vignati S, et al. Novel GC-rich DNA-binding compound produced by a genetically engineered mutant of the mithramycin producer Streptomyces argillaceus exhibits improved transcriptional repressor activity: implications for cancer therapy. Nucleic Acids Res 2006;34:1721-1734
38. Bonofiglio D, Qi H, Gabriele S, et al. Peroxisome proliferator-activated receptor g inhibits follicular and anaplastic thyroid carcinoma cells growth by upregulating p21Cip1/WAF1 gene in a Sp1-dependent manner. Endocr Relat Cancer 2008;15:545-557 (Pubitemid 351880842)
39. Wang CH, Tsao YP, Chen HJ, Chen HL, Wang HW, Chen SL. Transcriptional repression of p21((Waf1/Cip1/Sdi1)) gene by c-jun through Sp1 site. Biochem Biophys Res Commun 2000;270:303-310
40. Huang W, Tan D, Wang X, et al. Histone deacetylase 3 represses p15(INK4b) and p21(WAF1/cip1) transcription by interacting with Sp1. Biochem Biophys Res Commun 2006;339:165-171 (Pubitemid 41697530)
41. Mottet D, Pirotte S, Lamour V, et al. HDAC4 represses p21(WAF1/Cip1) expression in human cancer cells through a Sp1-dependent, p53-independent mechanism. Oncogene 2009;28:243-256
42. Wilson AJ, Byun DS, Nasser S, et al. HDAC4 promotes growth of colon cancer cells via repression of p21. Mol Biol Cell 2008;19:4062-4075
43. Lin YC, Lin JH, Chou CW, Chang YF, Yeh SH, Chen CC. Statins increase p21 through inhibition of histone deacetylase activity and release of promoter-associated HDAC1/2. Cancer Res 2008;68:2375-2383
44. Majid S, Kikuno N, Nelles J, et al. Genistein induces the p21WAF1/CIP1 and p16INK4a tumor suppressor genes in prostate cancer cells by epigenetic mechanisms involving active chromatin modification. Cancer Res 2008;68:2736-2744 (Pubitemid 351556271)
45. Kumagai T, Wakimoto N, Yin D, et al. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (Vorinostat, SAHA) profoundly inhibits the growth of human pancreatic cancer cells. Int J Cancer 2007;121:656-665 (Pubitemid 46986501)
46. Glaser KB, Staver MJ, Waring JF, Stender J, Ulrich RG, Davidsen SK. Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol Cancer Ther 2003;2:151-163
47. Fang Z, Fu Y, Liang Y, et al. Increased expression of integrin h1 subunit enhances p21WAF1/Cip1 transcription through the Sp1 sites and p300-mediated histone acetylation in human hepatocellular carcinoma cells. J Cell Biochem 2007;101:654-664 (Pubitemid 46698850)
48. Garcia-Bassets I, Kwon YS, Telese F, et al. Histone methylation-dependent mechanisms impose ligand dependency for gene activation by nuclear receptors. Cell 2007;128:505-518 (Pubitemid 46198894)
49. Scoumanne A, Chen X. The lysine-specific demethylase 1 is required for cell proliferation in both p53-dependent and -independent manners. J Biol Chem 2007;282:15471-15475 (Pubitemid 47093261)